chronic spontaneous urticaria
GPTKB entity
Statements (48)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:disease
skin disorder |
| gptkbp:affects |
gptkb:skin
subcutaneous tissue |
| gptkbp:alsoKnownAs |
gptkb:CSU
gptkb:chronic_idiopathic_urticaria |
| gptkbp:associatedWith |
thyroid disease
autoantibodies allergies infections |
| gptkbp:canBeChronic |
yes
|
| gptkbp:canBeSpontaneous |
yes
|
| gptkbp:cause |
unknown
|
| gptkbp:causedBy |
specific external triggers
|
| gptkbp:complication |
impaired quality of life
|
| gptkbp:diagnosedBy |
clinical evaluation
exclusion of other causes |
| gptkbp:differentialDiagnosis |
gptkb:contact_dermatitis
urticarial vasculitis physical urticaria |
| gptkbp:duration |
more than 6 weeks
|
| gptkbp:firstLine |
second-generation antihistamines
|
| gptkbp:fourthLineTreatment |
immunosuppressants
|
| gptkbp:frequency |
daily or almost daily symptoms
|
| gptkbp:gender |
more common in women
|
| https://www.w3.org/2000/01/rdf-schema#label |
chronic spontaneous urticaria
|
| gptkbp:ICD-10_code |
L50.1
|
| gptkbp:MeSH_ID |
D014581
|
| gptkbp:onset |
childhood
adulthood |
| gptkbp:pathology |
histamine release
mast cell activation |
| gptkbp:prevalence |
about 0.5-1% of the population
|
| gptkbp:prognosis |
often resolves within 2-5 years
|
| gptkbp:riskFactor |
stress
autoimmune diseases |
| gptkbp:secondLineTreatment |
increased dose antihistamines
|
| gptkbp:symptom |
itching
hives angioedema |
| gptkbp:thirdLineTreatment |
gptkb:omalizumab
|
| gptkbp:treatment |
gptkb:omalizumab
corticosteroids antihistamines leukotriene receptor antagonists |
| gptkbp:bfsParent |
gptkb:chronic_idiopathic_urticaria
gptkb:omalizumab |
| gptkbp:bfsLayer |
6
|